Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000902664-25-003639
Filing Date
2025-08-14
Accepted
2025-08-14 16:08:54
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 8944
2 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13D-1(K) p25-1741exhibit991.htm EX-99.1 4446
  Complete submission text file 0000902664-25-003639.txt   15082
Mailing Address 1001 10TH AVENUE SOUTH SUITE 216 NAPLES FL 34102
Business Address 1001 10TH AVENUE SOUTH SUITE 216 NAPLES FL 34102 239-384-9750
Pentwater Capital Management LP (Filed by) CIK: 0001425851 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE
Type: SCHEDULE 13G

Mailing Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215 (978) 501-3026
Verve Therapeutics, Inc. (Subject) CIK: 0001840574 (see all company filings)

EIN.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-92605 | Film No.: 251218981
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)